FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563478049> ?p ?o ?g. }

• W2563478049 abstract "Glioblastoma (GBM) is the most common type of primary brain tumor with poor prognosis. A gender bias exists in the development of GBM with incidence of developing GBM is greater in males compared to females. Epidemiological studies and several lines of evidence suggest tumor suppressive role of female sexual hormone estrogen on brain tumors. However, estrogen as potential therapy for GBM has limited therapeutic application due to safety concerns including breast cancer, uterine cancer, heart disease, and feminization in men. Therefore alternative agents that mimic estrogen effects will have potent utility in treating GBM. Estrogen effects are mediated though its cognate receptors ERα and ERβ and ERβ functions as a tissue-specific tumor suppressor. Recent studies identified a synthetic LY500307 as a selective ERβ agonist (developed by Eli Lilly and Company) with an excellent preclinical profile and is currently in clinical trials for treating Schizophrenia. We recently showed that ERβ is the major ER subtype expressed in GBM. The objective of this study is to determine the therapeutic effects of novel ERβ agonist LY500307 using both in vitro and orthotopic preclinical models and to determine its mechanism(s) of action. In this study, we have tested the therapeutic efficacy of LY500307 using several established as well as patient derived GBM cells. Treatment of LY500307 significantly reduced the proliferation of GBM cells with no activity on normal astrocytes suggesting its tumor specific effects. Overexpression of ERβ reduced proliferation of GBM cells and knockdown of ERβ compromised the treatment effect of LY500307 further suggesting the specificity. RNA sequencing analysis of LY500307 treated and untreated GBM cells revealed several novel pathways related to apoptosis, cell cycle, stem cells and differentiation that were significantly modulated by LY500307. Mechanistic studies revealed that LY500307 mediated apoptosis of GBM involve genes activated by both ERβ- classical as well as AP1 mediated non-classical pathways and also involve p38MAPK and JNK pathways. Since Glioma Stem Cells (GSCs) are implicated in tumor initiation, invasion and therapy resistance of GBM, we also tested the effect of LY500307 on GSCs. LY500307 treatment significantly inhibited the proliferation, neurosphere formation and self-renewal of GSCs and also resulted in the loss of stemness of GSCs and induction of differentiation and apoptosis. Further, LY500307 treatment significantly reduced the tumor growth in in vivo orthotopic GBM models and promoted apoptosis of tumors. Together, our results demonstrate that LY500307 as a potential therapeutic agent for treatment of GBM. Since LY500307 has good blood-brain barrier permeability and less neuronal toxicity, it can be readily transferred to clinical use with current radiation and chemotherapies, thereby providing an additional tool for enhancing survival in GBM patients. Citation Format: Gangadhara R. Sareddy, Aleksandra Gruslova, David A. Cavazos, Rajeshwar R. Tekmal, Andrew J. Brenner, Ratna K. Vadlamudi. LY500307 as a novel therapeutic agent for treatment of glioblastoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 951. doi:10.1158/1538-7445.AM2015-951" @default.
• W2563478049 created "2017-01-06" @default.
• W2563478049 creator A5014461472 @default.
• W2563478049 creator A5030664008 @default.
• W2563478049 creator A5054763940 @default.
• W2563478049 creator A5060877175 @default.
• W2563478049 creator A5083922162 @default.
• W2563478049 creator A5090010000 @default.
• W2563478049 date "2015-08-01" @default.
• W2563478049 modified "2023-09-27" @default.
• W2563478049 title "Abstract 951: LY500307 as a novel therapeutic agent for treatment of glioblastoma" @default.
• W2563478049 doi "https://doi.org/10.1158/1538-7445.am2015-951" @default.
• W2563478049 hasPublicationYear "2015" @default.
• W2563478049 type Work @default.
• W2563478049 sameAs 2563478049 @default.
• W2563478049 citedByCount "0" @default.
• W2563478049 crossrefType "proceedings-article" @default.
• W2563478049 hasAuthorship W2563478049A5014461472 @default.
• W2563478049 hasAuthorship W2563478049A5030664008 @default.
• W2563478049 hasAuthorship W2563478049A5054763940 @default.
• W2563478049 hasAuthorship W2563478049A5060877175 @default.
• W2563478049 hasAuthorship W2563478049A5083922162 @default.
• W2563478049 hasAuthorship W2563478049A5090010000 @default.
• W2563478049 hasConcept C121608353 @default.
• W2563478049 hasConcept C126322002 @default.
• W2563478049 hasConcept C143998085 @default.
• W2563478049 hasConcept C170493617 @default.
• W2563478049 hasConcept C173396325 @default.
• W2563478049 hasConcept C2777164284 @default.
• W2563478049 hasConcept C2777176818 @default.
• W2563478049 hasConcept C2778938600 @default.
• W2563478049 hasConcept C502942594 @default.
• W2563478049 hasConcept C530470458 @default.
• W2563478049 hasConcept C54355233 @default.
• W2563478049 hasConcept C71924100 @default.
• W2563478049 hasConcept C81885089 @default.
• W2563478049 hasConcept C84606932 @default.
• W2563478049 hasConcept C86803240 @default.
• W2563478049 hasConceptScore W2563478049C121608353 @default.
• W2563478049 hasConceptScore W2563478049C126322002 @default.
• W2563478049 hasConceptScore W2563478049C143998085 @default.
• W2563478049 hasConceptScore W2563478049C170493617 @default.
• W2563478049 hasConceptScore W2563478049C173396325 @default.
• W2563478049 hasConceptScore W2563478049C2777164284 @default.
• W2563478049 hasConceptScore W2563478049C2777176818 @default.
• W2563478049 hasConceptScore W2563478049C2778938600 @default.
• W2563478049 hasConceptScore W2563478049C502942594 @default.
• W2563478049 hasConceptScore W2563478049C530470458 @default.
• W2563478049 hasConceptScore W2563478049C54355233 @default.
• W2563478049 hasConceptScore W2563478049C71924100 @default.
• W2563478049 hasConceptScore W2563478049C81885089 @default.
• W2563478049 hasConceptScore W2563478049C84606932 @default.
• W2563478049 hasConceptScore W2563478049C86803240 @default.
• W2563478049 hasLocation W25634780491 @default.
• W2563478049 hasOpenAccess W2563478049 @default.
• W2563478049 hasPrimaryLocation W25634780491 @default.
• W2563478049 hasRelatedWork W1508407537 @default.
• W2563478049 hasRelatedWork W1836950607 @default.
• W2563478049 hasRelatedWork W1985798182 @default.
• W2563478049 hasRelatedWork W2029967050 @default.
• W2563478049 hasRelatedWork W2045318349 @default.
• W2563478049 hasRelatedWork W2050135095 @default.
• W2563478049 hasRelatedWork W2114884660 @default.
• W2563478049 hasRelatedWork W2124556650 @default.
• W2563478049 hasRelatedWork W2146519891 @default.
• W2563478049 hasRelatedWork W2342089507 @default.
• W2563478049 hasRelatedWork W2343042738 @default.
• W2563478049 hasRelatedWork W2538268343 @default.
• W2563478049 hasRelatedWork W2584318465 @default.
• W2563478049 hasRelatedWork W2774367756 @default.
• W2563478049 hasRelatedWork W2911881832 @default.
• W2563478049 hasRelatedWork W2966134498 @default.
• W2563478049 hasRelatedWork W3163079392 @default.
• W2563478049 hasRelatedWork W3183310001 @default.
• W2563478049 hasRelatedWork W3189746644 @default.
• W2563478049 hasRelatedWork W3199574626 @default.
• W2563478049 isParatext "false" @default.
• W2563478049 isRetracted "false" @default.
• W2563478049 magId "2563478049" @default.
• W2563478049 workType "article" @default.